Skip to main content
. Author manuscript; available in PMC: 2019 Nov 15.
Published in final edited form as: Cancer Res. 2018 Oct 4;78(22):6363–6370. doi: 10.1158/0008-5472.CAN-18-1429

Figure 2. Anti-tumor activity of anti-CTLA-4 DMAb in Sa1N and CT26 tumor models.

Figure 2.

A) Tumor study outline for DMAb delivery using prophylactic Sa1N tumor model in A/J mice (top), and serum levels of anti-CTLA-4 mouse IgG from these mice (bottom). 400μg DMAb was delivered by IM-EP 4 days prior to implantation of tumor cells. B) Tumor volume measurements and survival analysis of the mice described in A. C) Tumor study outline for DMAb delivery using therapeutic CT26 tumor model in Balb/c mice (top), and serum levels of anti-CTLA-4 mouse IgG from these mice (bottom). 400μg DMAb was delivered by IM-EP 3 days after implantation of CT26 tumor cells. D) Tumor volume measurements and survival analysis of the mice described in C. Error bars indicate mean ±SEM. N=10 mice per group. Shown is a representative of two independent experiments.